A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

Hypomethylating agents (HMA) prolong survival and improve cytopenias in individuals with higher-risk myelodysplastic syndrome (MDS). Only 30-40% of patients, however, respond to HMAs, and responses may not occur for more than 6 months after HMA initiation. We developed a model to more rapidly assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Radakovich, Nathan, Sallman, David A., Buckstein, Rena, Brunner, Andrew, Dezern, Amy, Mukerjee, Sudipto, Komrokji, Rami, Al-Ali, Najla, Shreve, Jacob, Rouphail, Yazan, Parmentier, Anne, Mamedov, Alexandre, Siddiqui, Mohammed, Guan, Yihong, Kuzmanovic, Teodora, Hasipek, Metis, Jha, Babal, Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Nazha, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490588/
https://www.ncbi.nlm.nih.gov/pubmed/36157589
http://dx.doi.org/10.1016/j.isci.2022.104931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490588/
https://www.ncbi.nlm.nih.gov/pubmed/36157589
http://dx.doi.org/10.1016/j.isci.2022.104931

Ejemplares similares